- Conditions
- Pmm2-CDG, Phosphomannomutase 2 Deficiency
- Interventions
- GLM101
- Drug
- Lead sponsor
- Glycomine, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more
Location Directory
Clinical trials in Minneapolis, Minnesota
This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7857
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 253–264 of 7,857 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Obesity
- Interventions
- Sham Transcranial Direct Current Stimulation (tDCS), Active Transcranial Direct Current Stimulation (tDCS)
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
- Interventions
- Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium, Paclitaxel, Ramucirumab
- Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 536
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 357 more
- Conditions
- COVID-19, Sars-CoV-2 Infection
- Interventions
- NVX-CoV2705, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 6,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 99
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
- Conditions
- Pleuropulmonary Blastoma
- Interventions
- Vincristine, Dactinomycin, Cyclophosphamide, Ifosfamide, Doxorubicin
- Drug
- Lead sponsor
- Children's Hospitals and Clinics of Minnesota
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2035
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Ovarian Sex-cord Stromal Tumor, Testicular Stromal Tumors, Ovarian Small Cell Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Children's Hospitals and Clinics of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2035
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine
- Procedure · Drug · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Duarte, California • Dublin, California + 127 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 989
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more
- Conditions
- Chronic TMD Pain, Temporomandibular Disorder
- Interventions
- Local Heat Therapy
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Stickler Syndrome Type 1, Stickler Syndrome Type 2
- Interventions
- Prophylactic (non-invasive) Laser Retinopexy
- Procedure
- Lead sponsor
- Helen Keller Eye Research Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Royal Oak, Michigan + 3 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
- Interventions
- Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 739 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 709
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 69 more